Opinion statement Carcinoid syndrome (CS) is a complex disorder caused by functional
neuroendocrine tumors (NETs). This debilitating disease is characterized by hyper-secretion …

Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in
patients with well differentiated neuroendocrine tumors (NETs), with somatostatin analogs …

“Carcinoids” are mostly slow-growing neuroendocrine neoplasms (NENs) with low
proliferative activity. A wide range of therapeutic options with variable efficacy exist …

discussion The therapeutic options for refractory carcinoid syndrome are limited. The
development of new targeted agents for the treatment of neuroendocrine tumors (NET) has …

This review reports on the currently available medical treatment options for the control of
symptoms due to carcinoid syndrome in patients with neuroendocrine tumors. The efficacy …

Neuroendocrine tumours (NETs) arise from neuroendocrine cells of the gastrointestinal tract,
pancreas, bronchi or other rare primary sites and comprise a variety of different tumour …

Opinion statement Neuroendocrine tumors (NET) represent a complex and heterogeneous
group of malignancies arising from the diffuse endocrine cells and other cells derived from …

Neuroendocrine tumours (NETs) arise from the gastrointestinal tract, pancreas, bronchi or
other rare primary sites and comprise a variety of different tumour types. Carcinoid tumours …

268 Background: Somatostatin analogs (SSAs) are the mainstay treatment for carcinoid
syndrome. LAN is a long-acting SSA approved for this indication in> 50 countries, but not yet …

Carcinoid syndrome, a paraneoplastic condition linked with the release of multiple humoral
factors, affects around 30-40% of patients with well-differentiated neuroendocrine tumours …